Could Tiny Silica Particles Solve the Problem of Taking Peptide Drugs by Mouth? | Research

The takeaway

Mesoporous silica nanoparticles show strong potential as carriers that could protect peptide drugs from digestion and enable effective oral delivery.

Oral Peptide Delivery Challenge
Peptides have poor oral bioavailability due to enzymatic degradation and low membrane permeability — MSNs offer a nanoparticle-based solution with tailorable pore sizes and stimuli-responsive release

What the researchers found

Mesoporous silica nanoparticles (MSNs) offer multiple advantages for oral peptide delivery: their pore size and surface can be precisely tailored to load and protect peptides, they have high surface area for drug loading, excellent thermal stability, and good biocompatibility. MSNs can be engineered to respond to specific stimuli (such as pH changes in the gut) to control when and where peptides are released, potentially overcoming the major barriers of enzymatic degradation, poor membrane permeability, and low bioavailability that currently limit oral peptide therapeutics.

Why it matters

Most peptide drugs currently require injection, which limits patient compliance and accessibility. If mesoporous silica nanoparticles can successfully protect peptides through the digestive tract and deliver them intact, it could transform how peptide therapies are administered — making them as simple as taking a pill instead of requiring needles.

How the study worked

The researchers conducted a comprehensive literature review examining the challenges of oral protein and peptide delivery, strategies to overcome absorption barriers, and the specific role of mesoporous silica nanoparticles as delivery vehicles. They analyzed published studies on MSN design, peptide loading mechanisms, stimuli-responsive release systems, and gene transfection applications.

What this study cannot tell us

This is a review paper without original experimental data. The authors note that potential risks of mesoporous silica nanoparticles — including long-term toxicity, biodegradation, and organ accumulation — still need to be thoroughly addressed before clinical translation. Most cited studies are preclinical, and oral peptide delivery via MSNs has not yet been validated in human trials.

How to read the evidence

As a review article synthesizing existing literature, this paper does not present original experimental data. It provides a comprehensive overview of the field but relies on preclinical studies, and the MSN approach has not yet been validated in human clinical trials.

When this study was published

Published in 2023, this review covers the current state of mesoporous silica nanoparticle research for peptide delivery, an actively evolving field.

The bigger picture

The peptide therapeutics market is booming, but the injection requirement remains a major barrier. This review sits at the intersection of nanotechnology and peptide science, exploring one of the most promising approaches to oral peptide delivery. If MSN-based carriers can clear safety hurdles, they could dramatically expand access to peptide treatments for conditions ranging from diabetes to cancer.

Questions still open

What are the long-term safety profiles of mesoporous silica nanoparticles when taken orally over extended periods?
Can MSN-based oral delivery achieve bioavailability comparable to injectable peptide formulations?
Which specific peptide therapeutics are closest to successful oral delivery using this nanoparticle approach?

Common questions

Why can't most peptide drugs be taken as pills today?

Peptides are large molecules that get broken down by stomach acid and digestive enzymes before they can be absorbed into the bloodstream. They also have difficulty passing through the intestinal lining. This is why most peptide drugs like insulin currently require injection.

What makes mesoporous silica nanoparticles promising for oral peptide delivery?

MSNs have tiny, customizable pores that can hold peptide molecules, protecting them from digestive enzymes. Their surfaces can be modified to control when and where the peptides are released, and they can be designed to respond to conditions like pH changes in the gut to deliver their payload at the optimal absorption site.

Read the original research

Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides.

Colloids and surfaces. B, Biointerfaces, 232, 113613

View on PubMed ↗Publisher’s paper ↗

Citation

Pamshong, Sharon Rose; Bhatane, Dhananjay; Sarnaik, Santosh; Alexander, Amit. (2023). Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides.. Colloids and surfaces. B, Biointerfaces, 232, 113613. https://doi.org/10.1016/j.colsurfb.2023.113613